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Abstract The clinical efficacy in
migraine was compared for oral
and subcutaneous sumatriptan and
naratriptan. Doses of the two
administration forms were chosen
as resulting in comparable blood
concentrations. Subcutaneous
administrations of the drugs were
superior for efficacy than the oral
forms. This most likely due to a
quicker rise in blood concentra-
tions after subcutaneous injec-
tions.. In designing new therapies
for migraine one should aim at a
quick absorption of the drug,
which will probably result in an
increased efficacy.
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The pharmacokinetic/pharmacodynamic relationship for
triptans in migraine has rarely been investigated [1–3]. In
one study patients were selected as non-responders, respon-
ders and patients with headache recurrence and the pharma-
cokinetic parameters for sumatriptan outside attacks were
compared [3]. No differences were found [3]. In addition, the
effect of sumatriptan on the common carotid artery and its
branches was quite comparable among the groups [3].
Ideally, one should use simultaneous measurements of plas-
ma levels of the drug and pharmacodynamics, in this case the
headache response. This approach has only been used in one
small pharmacokinetic study in which 11 of 20 patients
responded to oral zolmitriptan [1]. The plasma concentra-
tions of zolmitriptan were generally higher in responders
than in non-responders [1].
In a meta-analysis subcutaneous sumatriptan was supe-
rior to oral sumatriptan [4, 5] and it has been suggested
that the higher efficacy rate for subcutaneous sumatriptan
is dependent on a quicker speed of absorption [6, 7]. The
present comment is an attempt to explore this point further.
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Methods and results
Pharmacokinetic data for sumatriptan and naratriptan were taken
from studies in healthy volunteers in the literature [4, 5, 8] and for
subcutaneous naratriptan from a study in migraine patients [9].
These pharmacokinetic data were compared with the efficacy of
subcutaneous and oral sumatriptan and naratriptan in randomised
clinical trials [6, 9, 10].
Doses for comparison of subcutaneous and oral drugs were
selected as those resulting in roughly similar maximum plasma lev-
els (Cmax). For the chosen doses of sumatriptan (subcutaneous 6 mg
and oral 300 mg) and naratriptan (subcutaneous 1 mg and oral 2.5
mg) the Cmax, time to maximum concentration (Tmax) and therapeutic
gain (TG) (percentage response after active drug minus percentage
response after placebo) are shown in Table 1.
The oral bioavailability for sumatriptan is 14% [8], which is
substantially lower than its subcutaneous bioavailability of 96% [8].
The oral bioavailability is decreased further by 20% during
migraine attacks [8]. The Cmax for subcutaneous sumatriptan 6 mg is
72 ng/ml, whereas the Cmax is 112 ng/ml for oral sumatriptan 300 mg
[8]. For subcutaneous sumatriptan 6 mg the TG for headache relief
(a decrease from moderate or severe headache to none or mild) [11]
is 51% after 1 h [8]. After 2 h the headache relief increases to
81%–87% but the TG for subcutaneous sumatriptan remains the
same (50%) because the placebo response increases corresponding-
ly [6]. For oral sumatriptan 300 mg the TG for headache relief is
40% after 2 h [12]. The Tmax is 10 min for subcutaneous sumatriptan
6 mg [4] and the Tmax is 3 h for oral sumatriptan 300 mg [8].
The oral bioavailability of naratriptan is 74% [4] and there is a
virtually complete subcutaneous bioavailability [9]. For naratriptan
pain-free responses at 2 h, the currently suggested primary efficacy
measure [11] is available. The TG for pain-free is only 16% for oral
naratriptan 2.5 mg [10] and it is 27% for subcutaneous naratriptan
1 mg [9]. The Cmax is 13 ng/ml for oral naratriptan 2.5 mg [8] and
the Cmax is 16 ng/ml for subcutaneous 1 mg [9]. The Tmax is 10–20
min for subcutaneous naratriptan [9] and the Tmax for oral naratrip-
tan is 2 h [4].
Comments
Thus, for both triptans in doses resulting in roughly similar
maximum plasma levels after subcutaneous and oral admin-
istrations (Table 1) one gets a higher headache response with
the subcutaneous formulation.
A prerequisite for considering the pharmacokinetic/phar-
macodynamic relationship is an established dose-response
curve. There are dose-response curves for both subcutaneous
sumatriptan (1–8 mg) [4, 13, 14] and subcutaneous naratrip-
tan (0.5–10 mg) [9]. For oral naratriptan there is a dose-
response curve from 0.1 to 10 mg, with 1 mg being the min-
imum effective dose [15–17]. However, the dose-response
curve for oral sumatriptan is poorly defined. Sumatriptan
100 mg (60%–67%) is not different from 200 mg (73%) and
300 mg (71%) [12]. This could be due to a ceiling effect for
oral sumatriptan. That a ceiling effect is not inherent to trip-
tans per se is illustrated by the fact that the highest subcuta-
neous dose, naratriptan 10 mg, resulted in 88% pain-free
after 2 h [9, 18]. The badly defined dose-response curve for
oral sumatriptan makes the comparison of subcutaneous and
oral sumatriptan somewhat difficult and the results for suma-
triptan should therefore be judged with some reservation.
Another confounding factor is the possible influence of the
migraine attack with gastric stasis resulting in delayed oral
absorption of drugs [19, 20]. The oral bioavailability of suma-
triptan is thus 20% lower during migraine attacks [8] and the
Cmax for sumatriptan 300 mg is probably reduced to a similar
extent during a migraine attack. For oral naratriptan the Tmax
increases from 2 h to 3.5 h during a migraine attack [21].
Both sumatriptan and naratriptan in the subcutaneous
administration form were apparently superior to the oral
form of the drugs (Table 1). It has been suggested that the
mechanism of headache relief could be correlated to the rate
of initial rise of plasma levels (Tmax), to the height of the plas-
ma levels (Cmax) or the amount of the drug absorbed, area
under the curve (AUC) [2]. The AUCs in the chosen doses
are smaller for subcutaneous than for the oral forms of suma-
triptan [6, 8] and naratriptan [6, 8, 9], so the total amount of
Table 1 Tmax, Cmax and therapeutic gaina for subcutaneous (s.c.) and oral sumatriptan and naratriptan (for choice of doses, see text)
Sumatriptan Naratriptan
6 mg s.c. 300 mg oral 1 mg s.c. 2.5 mg oral
Tmax (min) 10 180 10–20 120b
Cmax (ng/ml) 72 112c 16 13
Headache relief Pain-free
Therapeutic gain 51%d 40%e 27%e 16%e
a: percentage response after active drug minus percentage response after placebo; b: increases to 3.5 h during migraine attacks [21]; c: probably 20% lower during
migraine attacks [7]; d: after 1 h; e: after 2 h
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drug absorbed cannot explain the difference. The Cmax values
were roughly equivalent (Table 1). Therefore, the most like-
ly explanation for the differences in efficacy is the rapid ini-
tial rise in plasma levels, which is reflected in a shorter Tmax
(Table 1), after subcutaneous administration.
How earlier exposure to drugs results in a higher
response remains an enigma. Investigations on blood vessels
in vitro could elucidate whether similar responses occur in
isolated cranial arteries. If present there are possibilities to
study this further with pharmacological investigations at the
receptor level.
From a clinical point of view subcutaneous administra-
tion is optimal when a really quick effect is needed. Thus the
quick absorption of subcutaneous sumatriptan 6 mg results
in a clinically relevant TG for headache relief of 22% already
after 20 min in migraine [5]. It is also very effective in short-
lasting but very severe cluster headache attacks, with a TG of
48% within 15 min [22].
Subcutaneous naratriptan 10 mg was superior to subcu-
taneous sumatriptan 6 mg for pain-free: difference=+33%
(95% confidence intervals: +15% to +51%) [9, 18]. This
may be due to the higher potency of naratriptan. Thus the
pKi for inhibition of radioactive ligand binding for 5-HT1B is
8.1–8.7 for naratriptan and 7.8 for sumatriptan [4]. In addi-
tion, naratriptan is 2–3-fold more potent than sumatriptan in
some animal models relevant for migraine [23].
Subcutaneous naratriptan was, however, not developed fur-
ther for subcutaneous use but was developed in a low oral
dose of 2.5 mg causing no more adverse events than place-
bo [10, 18].
Even if subcutaneous injections are more effective than
tablets, most patients prefer to use tablets and the high price
for subcutaneous sumatriptan (€35 per injection in
Denmark) is also prohibitive in many cases.
In conclusion, the subcutaneous route of administration
of a triptan is superior to the oral route. This is most likely
due to the rapid initial rise in blood levels after the subcuta-
neous injection. In designing new therapies for migraine one
should aim at a quick absorption of the drug, which will
probably result in an increased efficacy.
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